No One Should Die Of Cancer
Platform & Preclinical Pipeline
Angiex’s Nuclear Delivery PlatformTM consists of proprietary TM4SF1-directed antibodies, site-specific conjugation method, and linkers. A wide range of drug payloads, including traditional chemotherapies and targeted small molecules as well as newer modalities like protein degraders and RNA, can be conjugated to make Nuclear-Delivered Antibody-Drug ConjugatesTM (ND-ADCs).
Angiex’s pipeline includes a diverse portfolio of discovery-stage ND-ADCs.